Frailty and Clinical Outcomes in Patients Treated With Hemodialysis: A Prospective Cohort Study

Marcello Tonelli; Natasha Wiebe; John S Gill; Aminu K Bello; Brenda R Hemmelgarn; Christopher T Chan; Anita Lloyd; Ravi I Thadhani; Stephanie Thompson

doi:10.1016/j.xkme.2023.100684

Frailty and Clinical Outcomes in Patients Treated With Hemodialysis: A Prospective Cohort Study

Kidney Med. 2023 Jun 1;5(8):100684. doi: 10.1016/j.xkme.2023.100684. eCollection 2023 Aug.

Authors

Marcello Tonelli¹, Natasha Wiebe², John S Gill³, Aminu K Bello², Brenda R Hemmelgarn², Christopher T Chan⁴, Anita Lloyd², Ravi I Thadhani⁵, Stephanie Thompson²

Affiliations

¹ Department of Medicine, University of Calgary, Canada.
² Department of Medicine, University of Alberta, Canada.
³ Department of Medicine, University of British Columbia, Canada.
⁴ Department of Medicine, University of Toronto, Canada.
⁵ Department of Medicine, Harvard University, MA.

Abstract

Rationale and objective: Frailty is common among people with kidney failure treated with hemodialysis (HD). The objective was to describe how frailty evolves over time in people treated by HD, how improvements in frailty and frailty markers are associate with clinical outcomes, and the characteristics that are associated with improvement in frailty.

Study design: Prospective cohort study.

Setting and participants: Adults initiating thrice weekly in-center HD in Canada.

Exposure: We classified frailty using a 5-point score (3 or more indicates frailty) based on physical inactivity, slowness or weakness, poor endurance or exhaustion, and malnutrition. We categorized the frailty trajectory as never present, improving, deteriorating, and always present.

Outcomes: All-cause death, hospitalizations, and placement into long-term care.

Analytical approach: We examined the association between time-varying frailty measures and these outcomes using Cox and negative binomial models, after adjustment for potential confounders.

Results: 985 participants were included and followed up for a median of 33 months; 507 (51%) died, 761 (77%) experienced ≥1 hospitalization and 115 (12%) entered long-term care. Overall, 760 (77%) reported frailty during follow-up. Three-quarters (78%) of those with frailty at baseline remained frail throughout the follow-up, 46% without baseline frailty became frail, and 23% with baseline frailty became nonfrail. Higher frailty scores were associated with an increased risk of mortality (fully adjusted HR, 1.58 per unit; 95% CI, 1.39-1.80) and an increased rate of hospitalization (RR, 1.16 per unit; 95% CI, 1.09-1.23). Compared with those who were frail throughout the follow-up, participants with frailty at baseline but improving during follow-up showed a lower mortality (HR, 0.59; 95% CI, 0.42-0.81), and a lower rate of hospitalization (RR, 0.70; 95% CI, 0.56-0.87).

Limitations: There was missing data on frailty at baseline and during follow-up.

Conclusions: Frailty was associated with a higher risk of poor outcomes compared with those without frailty, and participants whose status improved from frail to nonfrail showed better clinical outcomes than those who remained frail. These findings emphasize the importance of identifying and implementing effective treatments for frailty in patients receiving maintenance HD.

Keywords: Kidney failure; chronic kidney disease; frailty; hemodialysis; physical activity.